MEDNAX (MD) Reports In-Line Q1 EPS; reaffirms guidance

MEDNAX (NYSE: MD) reported Q1 EPS of $0.23, in-line with the analyst estimate of $0.23. Revenue for the quarter came in at $491 million versus the consensus estimate of $490.56 million.

2023 Outlook

As previously disclosed, Pediatrix anticipates that its 2023 Adjusted EBITDA, as defined below, will be in a range of $235 million to $245 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Palo Alto Networks (PANW) Tops Q3 EPS by 6c, Offers Guidance
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance